Please login to the form below

IBD

This page shows the latest IBD news and features for those working in and with pharma, biotech and healthcare.

investigational IBD medicines.

M&F Health, 90TEN and Sanofi among big winners at Communiqué Awards

Sponsored by Cloud Talk. Winner: LOGIC IBD Nurse Education and Recognition Event.
Latecomer Lilly preps its IL-23 drug for Crohn’s disease

Tremfya also has data suggesting it works in Stelara-resistant psoriasis. Lilly’s antibody is still in phase 3 for psoriasis, well behind the leaders, but IBD presents a greater opportunity
Finch’s microbiota drug for C. diff gets FDA breakthrough status

Finch's CEO Mark Smith. Led by CEO Mark Smith, the company also has a two-year-old deal with Takeda to develop a microbiota treatment for irritable bowel disease (IBD).
BMS to test Vedanta’s bacterial therapy with Opdivo

The two companies have started treating patients in a phase 1 trial of VE202, another bacterial consortium aimed at treating inflammatory bowel disease (IBD). ... VE202 is based on the idea that IBD patients are deficient in certain Clostridia species in
Communiqué: big wins for obesity and sugar tax campaigners

Specialist healthcare communications group Sciterion (pictured below) won the Excellence in Communications via a Live Event or Stand-Alone Activity accolade for its Live Multi-site National IBD Meeting. ... Meanwhile, Aurora Healthcare Communications’

More from news
Approximately 11 fully matching, plus 32 partially matching documents found.

Deal Watch February 2017

The deal also includes a licence to AKB-5169 (formerly JNJ5169), an oral, preclinical stage compound for inflammatory bowel disease (IBD). . ... Joint venture. 286.3. Janssen/ Akebia Therapeutics. HIF-targeting candidates inc AKB-5169 for IBD (pc)
Deal Watch June 2016

IBD). PF-00547659 targets a gastrointestinal endothelial adhesion molecule known as mucosal addressin cell adhesion molecule 1 (MAdCAM-1) that binds to the α4β7 integrin on lymphocytes.
Deal Watch October 2015

Janssen's partnership with Canadian biotech enGene, facilitated through J&J Innovation, brings gene therapies for inflammatory bowel disease (IBD) and includes an undisclosed upfront payment and equity investment, R&D ... Research collaboration, option,
Pharma deals in June 2015

the treatment of inflammatory bowel disease (IBD). ... 130. Lycera Corporation/ Celgene Corporation. Orally bioavailable RORgamma agonists for ex vivo use lead programme, LYC-30937 (oral gut-directed ATPase modulator for IBD, p1).
Getting real about patient support

opposed to a series of acute episodes (such as in asthma, COPD or IBD).

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Takeda strengthens leadership team with business unit director

Takeda UK has appointed Craig Adkins as its new business unit director for irritable bowel disease (IBD). .

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Lucid Group bolsters its senior client services team with two magical new hires

She has experience across several different therapy areas, including diabetes, rare diseases and IBD.
Lucid Group strengthens its scientific leadership and client service team with two new hires

Lizzie has previously worked in Global, European, and UK roles with experience in several therapy areas including immuno-oncology, CIA, CKD, oral contraception, IBD, and wound care.
IBD Registry appoints first CEO

The IBD Registry is familiar to many as the first UK-wide collection of anonymised adult and paediatric IBD data for prospective audit and research. ... Liz brings to the IBD Registry 20 years of executive and senior management experience from the
Pharma and NHS working together for patients - the IBD Registry Industry Working Group

Recently, we spoke to members of the IBD Registry Industry Working Group about what they’ve achieved in their first year, and whether or not it’s been worthwhile.
Joined-up thinking on anaemia

Iron deficiency anaemia is very common in inflammatory bowel disease (IBD) and can seriously reduce people’s quality of life, but it’s often under-treated. ... The partners share resources and skills and the project is the first to use the IBD